EP0663208A2 — Combinations of polymers for use in artificial tear compositions
Assigned to Alcon Vision LLC · Expires 1995-07-19 · 31y expired
What this patent protects
Physiological tear compositions for the treatment of the eye are disclosed which have a high viscosity and contain bicarbonate, a cellulosic polymer and/or a glycosaminoglycan and/or a carboxy vinyl polymer. A claimed composition comprises: a) potassium ions at a concentration …
USPTO Abstract
Physiological tear compositions for the treatment of the eye are disclosed which have a high viscosity and contain bicarbonate, a cellulosic polymer and/or a glycosaminoglycan and/or a carboxy vinyl polymer. A claimed composition comprises: a) potassium ions at a concentration between about 11 and about 25 mmol/L; b) calcium ions at a concentration between about 0.2 and about 0.5 mmol/L; c) magnesium ions at a concentration between about 0.15 and about 0.45 mmol/L; d) bicarbonate ions at a concentration between about 1 and about 36 mmol/L; e) at least one component from a group consisting of i) a cellulosic polymer ii) a glycosaminoglycan iii) a carboxy vinyl polymer; and f) a viscosity between about 5 and about 10,000 centipoise. a
Drugs covered by this patent
- Lotemax (LOTEPREDNOL ETABONATE) · Bausch Health
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.